论文部分内容阅读
2008年9月19日美国FDA批准GE Health-care公司开发的放射性药物碘苄胍I 123静脉注射剂上市,该药商品名为AdreV iew,用于儿童和成人患者神经内分泌瘤的诊断。GE Healthcare公司于2004年开始开发本品,2006年12月美国FDA批准其为罕用药物。2008年3月GE Health-care公司递交了硫酸
September 19, 2008 FDA Approves Iodoguanidine I 123 Intravenous Injection Developed by GE Health-care as AdreView for the Diagnosis of Neuroendocrine Tumors in Children and Adults. GE Healthcare started to develop the product in 2004, and the FDA approved it as a rare drug in December 2006. March 2008 GE Health-care company submitted sulfuric acid